USA    |    Global :  English    简中    繁中    |    MAP
  Login    |     Shopping Cart
About CytoTest
  Company Overview
  Management Team
  News & Events
  Business Opportunities
  Job Opportunity
  Contact CytoTest

CytoTest and CapitalBio announce strategic collaborations


ROCKVILLE, Maryland, May 09, 2016  – CytoTest Inc. and CapitalBio Corporation, a leading life science company based  in Beijing, P. R. China, announced today that the two companies have entered into a strategic relationship.

To this end, a strategic collaboration agreement was signed by the companies in a formal ceremony at CapitalBio’s Medlab division headquarters in Beijing, on February 2, 2016.

The non-exclusive agreement initially includes joint development of state of the art molecular diagnostic assays, instrumentation and services. The companies intend to jointly pursue a number of complementary initiatives in research, product development and clinical testing in China, the United States and for worldwide markets. Other collaborative efforts under discussion include manufacturing certain products in China, taking advantage of CapitalBio’s unparalleled engineering and manufacturing capabilities.

While at the beginning focused on cooperation in diagnostic and prognostic test systems mainly for oncology and prenatal applications, the partners will expand their interaction to many other areas of unmet medical needs, with a strong emphasis on routes to early detection, non-invasive testing methods, and novel tools for precision medicine.

The collaboration combines CapitalBio’s unique genomic medicine, automation and diagnostic assay development infrastructure with CytoTest’s discovery and molecular cytogenetics expertise. Furthermore, the companies will share know-how and machinery toward the efficient application of their combined manufacturing abilities.

“We are excited to be entering this wide-ranging relationship with a world class partner such as CapitalBio,” said Joseph Cheng, President and CEO of CytoTest. “The collaboration is especially rewarding since scientists at both CapitalBio and CytoTest have been engaged in fruitful discussions for some time. Leveraging our unique and highly complementary resources for validating and optimizing genomics-based diagnostic assays, this agreement is an important milestone for CytoTest and will greatly facilitate the completion of several near-term product development and commercialization milestones. In addition, this agreement envisions a long-term working relationship that is very flexible and will allow the planning and implementation of many other mutually beneficial initiatives.”















  “The merging of our advanced detection technology and testing platforms, biochip-related product series and total health-care solutions with the reagent and expertise resources as well as the network of research collaborations of CytoTest in the United States is an arrangement with many complementary aspects and several advantages. We hope that we will see accelerated solution finding through the joint efforts of such a collaboration, and we are quite confident that it may in fact serve as a model of international cooperation in the field of molecular diagnostics,” said Mr. Bao-Ming Shi, Chairman of CapitalBio MedLab. “This exciting partnership between CapitalBio MedLab and CytoTest Inc. is a dynamic, highly mutual union and thus presents a win-win situation for both sides. We eagerly look forward to a successful and rewarding cooperation, fostering many advancements in molecular diagnostics between the USA and China.”


About CytoTest

CytoTest Inc., a young and dynamic biotechnology company, is dedicated to providing high-quality, innovative and affordable molecular cytogenetics products and services. Headquartered in suburban Maryland near Washington, D.C., it is situated close to several premier biological research and medical centers. With a multi-disciplinary team of passionate and dedicated researchers, and through spirited interactions with preeminent strategic partners in the academic, biotechnology and clinical communities, the company strives to stay at the forefront of diagnostic medicine.

CytoTest’s mission is to transform human genomic discoveries into useful products, and to design, manufacture and validate genetic and clinical diagnostics reagents with the highest quality. For more information about USU and its programs, visit


About CapitalBio

Headquartered in Beijing, China, CapitalBio is a leading life science Company that develops and commercializes total health-care solutions including a broad range of innovative biochip-related products for genomic, proteomic and cellomic research, bio-safety testing, clinical applications and to address wider human health needs. CapitalBio warmly encourages discussion of new business, marketing and production opportunities, etc. Both through innovation and a commitment to rapid product development, CapitalBio is seeking to reduce the cost of products, to benefit our customers.

For more information, visit




CytoTest Inc.  |  9430 Key West Avenue, Suite 210, Rockville, MD 20850, USA
Tel:1-855-CYTOTEST  |  +1-202-688-1188  |

© 2013 CytoTest Inc. All Rights Reserved.
Website Design | Youhome